Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY® (nipocalimab-aahu),c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results